Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Once Daily ◽

Faculty Opinions recommendation of Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718489447.793532747 ◽

2017 ◽

Author(s):

Ravi Kalhan ◽

Sharon R Rosenberg

Keyword(s):

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Once Daily ◽

Sugarcane bagasse dietary fiber as an adjuvant therapy for stable chronic obstructive pulmonary disease: a four-center, randomized, double-blind, placebo-controlled study

Journal of Traditional Chinese Medicine ◽

10.1016/s0254-6272(16)30057-7 ◽

2016 ◽

Vol 36 (4) ◽

pp. 418-426 ◽

Cited By ~ 1

Author(s):

Liu Miao ◽

Zheng Fengjie ◽

Ni Lei ◽

Sun Yan ◽

Wu Ruohan ◽

...

Keyword(s):

Adjuvant Therapy ◽

Dietary Fiber ◽

Pulmonary Disease ◽

Sugarcane Bagasse ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

BMJ ◽

10.1136/bmj.320.7245.1297 ◽

2000 ◽

Vol 320 (7245) ◽

pp. 1297-1303 ◽

Cited By ~ 931

Author(s):

P S Burge

Keyword(s):

Fluticasone Propionate ◽

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study

BMC Pulmonary Medicine ◽

10.1186/1471-2466-14-158 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 28

Author(s):

Henrik Watz ◽

Felix Krippner ◽

Anne Kirsten ◽

Helgo Magnussen ◽

Claus Vogelmeier

Keyword(s):

Physical Activity ◽

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Hyperinflation

Efficacy and Tolerability of Indacaterol 75 μg Once Daily in Patients Aged ≥40 Years With Chronic Obstructive Pulmonary Disease: Results From 2 Double-Blind, Placebo-Controlled 12-Week Studies

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.11.009 ◽

2011 ◽

Vol 33 (12) ◽

pp. 1974-1984 ◽

Cited By ~ 23

Author(s):

Edward M. Kerwin ◽

Mark H. Gotfried ◽

David Lawrence ◽

Cheryl Lassen ◽

Benjamin Kramer

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Double Blind ◽

Once Daily ◽

A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease

Clinical & Experimental Allergy ◽

10.1046/j.1365-2222.1999.00021.x ◽

1999 ◽

Vol 29 ◽

pp. 125-128 ◽

Cited By ~ 30

Author(s):

D. C. Weir ◽

G. A. Bale ◽

P. Bright ◽

P. Sherwood Burge

Keyword(s):

Pulmonary Disease ◽

Beclomethasone Dipropionate ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study

Journal of Pineal Research ◽

10.1111/j.1600-079x.2012.00992.x ◽

2012 ◽

Vol 53 (3) ◽

pp. 238-244 ◽

Cited By ~ 37

Author(s):

Antonio George de Matos Cavalcante ◽

Pedro Felipe Carvalhedo de Bruin ◽

Veralice Meireles Sales de Bruin ◽

Deuzilane Muniz Nunes ◽

Eanes Delgado Barros Pereira ◽

...

Keyword(s):

Oxidative Stress ◽

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Oxidative Stress

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Journal of Nuclear Cardiology ◽

10.1007/s12350-012-9547-4 ◽

2012 ◽

Vol 19 (4) ◽

pp. 681-692 ◽

Cited By ~ 48

Author(s):

Bruce M. Prenner ◽

Stan Bukofzer ◽

Sarah Behm ◽

Kathleen Feaheny ◽

Bruce E. McNutt

Keyword(s):

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study

Pulmonary Pharmacology ◽

10.1006/pulp.1995.1016 ◽

1995 ◽

Vol 8 (2-3) ◽

pp. 131-135 ◽

Cited By ~ 1

Author(s):

Niels A. Graudal ◽

Anders M. Galløe ◽

Inger Plum ◽

Nils Milman ◽

Jesper O. Clausen

Keyword(s):

Calcium Antagonist ◽

Pulmonary Disease ◽

Plasma Catecholamines ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Faculty Opinions recommendation of Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718313352.793493922 ◽

2014 ◽

Author(s):

Mark Dransfield ◽

Michael Wells ◽

Surya Bhatt

Keyword(s):

Pulmonary Disease ◽

Controlled Trial ◽

Chronic Obstructive ◽

Double Blind ◽